pharmaphorum

FEBRUARY 24, 2022

The UK’s health research data capabilities are rapidly evolving. For example, during the height of the pandemic, NIHR’s integrated health research system was able to compare COVID-19 hospital caseloads to COVID-19 research activity in real time. This enabled rapid recruitment to multiple COVID-19 clinical trials throughout England/UK. . In a post-pandemic world, how can we use insights gained from healthcare and research activity data to inform commercial research planning and placement decisio

Hospitals 97

Hospitals 97

Outsourcing Pharma

FEBRUARY 24, 2022

In its latest diversity, equity and inclusion report, Global Genes offers insight into obstacles faced by rare-disease patients from minority communities.

96

96

pharmaphorum

FEBRUARY 24, 2022

Clinical stage pharmaceutical company Cantex Pharmaceuticals has obtained a global licence from Harvard University’s Office of Technology Development to develop the small-molecule drug azeliragon into a treatment for inflammatory lung diseases, including COVID-19. Viral or bacterial infections, or airway irritants can damage lung cells, causing them to release damage associated molecular pattern (DAMP) molecules that attach to and activate the receptor for advanced glycation endproducts (RAGE) p

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies 64

Outsourcing Pharma

FEBRUARY 24, 2022

The AI-centered genomics company is joining with Donât Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.

64

64

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Mirror

FEBRUARY 24, 2022

Taking care of your mental health can be affordable. All you will have to do is choose therapy options that fit in your budget. In this article, we have outlined the most affordable therapy options. While the options fall in the lower price range, they are all capable of delivering your expected results. The post Ways to Access Affordable Mental Health Services appeared first on Pharma Mirror Magazine.

52

52

Roots Analysis

FEBRUARY 24, 2022

Since the approval of the first antisense therapy in 1998, oligonucleotides have been in light for their capabilities as therapeutic agents. Oligonucleotides are short synthetic nucleotide chains with immense potential in the diagnosis and treatment of a myriad of disease indications. In addition to therapeutics, these complex molecules act as a significant resource in various research applications.

52

52

Outsourcing Pharma

FEBRUARY 24, 2022

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

52

52

pharmaphorum

FEBRUARY 24, 2022

Team up, wake up, and act before AMR turns back the clock on medical advances, say the cross-sector team behind the Infection Management Coalition. It’s time for the entire healthcare ecosystem to come together and stop procrastinating on antimicrobial resistance (AMR) – or risk sleepwalking into an uncontrollable existential crisis. That’s according to some of the leading voices behind a whitepaper from the newly formed Infection Management Coalition (IMC), which calls on society to wake up and

Documentation 52

Documentation Vaccines 52

Pharma Times

FEBRUARY 24, 2022

No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial

63

63

pharmaphorum

FEBRUARY 24, 2022

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will now be recommended for routine use in the NHS. . Taken as a once-daily capsule, niraparib is a Poly ADP-ribose polymerase (PARP) inhibitor recommended as an option for treating patients with relapsed, platinum-sensitive high-grade serous

Chemotherapy 52

Chemotherapy 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

FEBRUARY 24, 2022

Pharma giants take major stride as vaccine shows significant increase in neutralising antibodies

Vaccines 43

Vaccines 43

pharmaphorum

FEBRUARY 24, 2022

Synthetic Control Arms (SCAs) have the potential to reduce the number of trial participants, eliminate delays, and lower costs. In this webinar experts from the worlds of clinical trials and clinical AI will present and discuss the factors to consider when planning to use an SCA as part of a clinical trial.

40

40

Pharma Mirror

FEBRUARY 24, 2022

Hoboken, NJ, Rostock/Berlin, Germany, Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion.

52

52

pharmaphorum

FEBRUARY 24, 2022

Hong Kong-based Insilico Medicine has begun a Phase 1 trial of its AI-discovered and AI-designed anti-fibrotic small molecule inhibitor. . Currently referred to as ISM001-055, the drug is meant to treat ideopathic pulmonary fibrosis using a relatively novel mechanism of action. Insilico announced in February of last year that they had identified and developed the molecule in less than 18 months, using the company’s target identification engine PandaOmics and its molecular generation engine

Dosage 40

Dosage 40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharma Mirror

FEBRUARY 24, 2022

Hoboken, NJ, Rostock/Berlin, Germany, Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion.

52

52